R3
Device
Smith & Nephew, Inc.
Total Payments
$2.1M
Transactions
370
Doctors
108
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $172,673 | 46 | 14 |
| 2020 | $176,975 | 52 | 12 |
| 2019 | $247,428 | 78 | 26 |
| 2018 | $423,219 | 101 | 38 |
| 2017 | $1.1M | 93 | 38 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $1.3M | 50 | 62.9% |
| Unspecified | $703,965 | 152 | 33.9% |
| Consulting Fee | $22,513 | 10 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,411 | 10 | 1.1% |
| Debt forgiveness | $9,706 | 1 | 0.5% |
| Travel and Lodging | $6,055 | 20 | 0.3% |
| Food and Beverage | $5,439 | 127 | 0.3% |
Payments by Type
General
$1.4M
218 transactions
Research
$703,965
152 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Post-Approval Study of the R3 Biolox delta Ceramic Acetabular System | Smith+Nephew, Inc. | $321,936 | 0 |
| R3 DoD FDA PAS | Smith+Nephew, Inc. | $234,094 | 0 |
| R3 DoD FDA PAS | Smith & Nephew, Inc. | $109,683 | 0 |
| A prospective, multicenter, non-randomized, clinical outcomes study of the R3 Acetabular System in patients with degenerative hip disease | Smith & Nephew, Inc. | $28,757 | 0 |
| A prospective, multicenter, non-randomized, clinical outcomes study of the R3 Acetabular System in patients with degenerative hip disease | Smith+Nephew, Inc. | $9,495 | 0 |
Top Doctors Receiving Payments for R3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $841,537 | 168 |
| , MD | Orthopaedic Surgery | Minneapolis, MN | $534,214 | 15 |
| , MD | Orthopaedic Surgery | Morton Grove, IL | $347,757 | 6 |
| , MD | Orthopaedic Surgery | Malvern, PA | $298,355 | 15 |
| , MD | Adult Reconstructive Orthopaedic Surgery | Lexington, KY | $12,208 | 9 |
| , M.D | Orthopaedic Surgery | New York, NY | $10,623 | 8 |
| , MD | Orthopaedic Surgery | Middlebury, CT | $7,500 | 1 |
| , M.D | Orthopaedic Surgery | Egg Harbor Township, NJ | $3,398 | 3 |
| , DO | Orthopaedic Surgery | Brighton, MI | $3,250 | 1 |
| , M.D | Adult Reconstructive Orthopaedic Surgery | Rancho Mirage, CA | $2,460 | 2 |
| , MD | Adult Reconstructive Orthopaedic Surgery | Omaha, NE | $2,210 | 2 |
| , M.D., M.SC | General Acute Care Hospital | Orange, CA | $2,000 | 1 |
| , MD | Orthopaedic Surgery | Southfield, MI | $1,546 | 2 |
| , M.D | Orthopaedic Surgery | Salem, NH | $1,232 | 2 |
| , DO | Student in an Organized Health Care Education/Training Program | Ames, IA | $956.27 | 1 |
| , MD | Orthopaedic Surgery | Savannah, GA | $787.00 | 13 |
| , DO | Surgery | Tulsa, OK | $734.40 | 1 |
| , M.D | Sports Medicine | Birmingham, AL | $640.72 | 2 |
| , M.D | Orthopaedic Surgery | Tallahassee, FL | $555.52 | 1 |
| , MD | Orthopaedic Surgery | Palestine, TX | $473.38 | 3 |
| , MD | Orthopaedic Surgery | Falmouth, ME | $444.90 | 3 |
| , MD | Orthopaedic Surgery | Delray Beach, FL | $415.54 | 1 |
| , M.D | Orthopaedic Surgery | Galveston, TX | $261.82 | 3 |
| , M.D | Orthopaedic Surgery | Madisonville, KY | $234.29 | 2 |
| , M.D | Specialist | Louisville, KY | $180.08 | 2 |
Ad
Manufacturing Companies
- Smith & Nephew, Inc. $1.5M
- Smith+Nephew, Inc. $597,076
Product Information
- Type Device
- Total Payments $2.1M
- Total Doctors 108
- Transactions 370
About R3
R3 is a device associated with $2.1M in payments to 108 healthcare providers, recorded across 370 transactions in the CMS Open Payments database. The primary manufacturer is Smith & Nephew, Inc..
Payment data is available from 2017 to 2021. In 2021, $172,673 was paid across 46 transactions to 14 doctors.
The most common payment nature for R3 is "Royalty or License" ($1.3M, 62.9% of total).
R3 is associated with 5 research studies, including "Post-Approval Study of the R3 Biolox delta Ceramic Acetabular System" ($321,936).